Kane Biotech Inc. - Biotechnology Company Focused on Developing Applications and Products for their Biofilm Technology
SNNLive spoke with Mark Ahrens-Townsend, President and CEO of Kane Biotech Inc. (TSX-V: KNE) at The MicroCap Conference 2017 in New York City, NY.
Monday, October 30, 2017
Kane Biotech (TSX-V: KNE) is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, according to the Company’s website (see here: www.kanebiotech.com).
SNNLive spoke with Mark Ahrens-Townsend, President and CEO of Kane Biotech Inc. at The MicroCap Conference 2017 in New York City, NY, and they discuss the following topics:
- Overview and history of Kane Biotech Inc.
- Biofilm industry
- Clinical Development
- Kane Biotech’s competitive advantage
- Mr. Ahrens-Townsend’s background
- Growth drivers
For more information about Kane Biotech Inc., please visit: www.kanebiotech.com
The interview may contain forward-looking statements about Kane Biotech Inc. See Kane Biotech Inc.'s periodic filings with SEDAR for more complete information.
More Commentary
-
Wednesday, June 19, 2019OneSoft Solutions, Inc. - Provides Corporate Development Update for First Half of 2019 and Growth Drivers for Rest of 2019
-
Tuesday, June 18, 2019US Nuclear Corp. - Radiation and Chemical Detection Holding Company Discusses Recent Corporate Developments and Growth Drivers for 2019
-
Thursday, June 13, 2019BioLargo, Inc. - Technology Developer & Environmental Engineering Company Discusses Revenue Growth, Product Adoption, Growth Drivers for Rest of 2019
- See More >
